Self-containing strain

- Actogenix N.V.

The invention relates to a recombinant Lactococcus strain, with environmentally limited growth and viability. More particularly, it relates to a recombinant Lactococcus that can only survive in a medium, where well-defined medium compounds are present. A preferred embodiment is a Lactococcus that may only survive in a host organism, where such medium compounds are present, but cannot survive outside the host organism in the absence of such medium compounds.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of PCT International Patent Application No. PCT/EP02/04942, filed on May 3, 2002, designating the United States of America, and published, in English, as PCT International Publication No. WO 02/090551 A2 on Nov. 14, 2002, the contents of the entirety of which are incorporated herein by this reference.

TECHNICAL FIELD

The invention relates to a recombinant Lactococcus strain, with environmentally limited growth and viability. More particularly, it relates to a recombinant Lactococcus that can only survive in a medium, where well-defined medium compounds are present. A preferred embodiment is a Lactococcus that may only survive in a host organism, where the medium compounds are present, but cannot survive outside the host organism in an absence of the medium compounds. Moreover, the Lactococcus can be transformed with prophylactic and/or therapeutic molecules and can, as such, be used to treat diseases such as inflammatory bowel diseases.

BACKGROUND

Lactic acid bacteria have long been used in a wide variety of industrial fermentation processes. They have generally-regarded-as-safe (“GRAS”) status, making them potentially useful organisms for the production of commercially important proteins. Indeed, several heterologous proteins, such as Interleukin-2, have been successfully produced in Lactococcus spp (Steidler et al., 1995). It is, however, undesirable that such genetically modified microorganisms survive and spread into the environment.

To avoid unintentional release of genetically modified microorganisms, special guidelines for safe handling and technical requirements for physical containment are used. Although this may be useful in industrial fermentations, the physical containment is generally considered as insufficient, and additional biological containment measures are taken to reduce the possibility of survival of the genetically modified microorganism in the environment.

Biological containment is extremely important in cases where physical containment is difficult or even inapplicable. This is, amongst others, the case in applications where genetically modified microorganisms are used as live vaccines or as a vehicle for delivery of therapeutic compounds. Such applications have been described, for example, in PCT. International Publication Number WO 97/14806, which discloses the delivery of biologically active peptides, such as cytokines, to a subject by recombinant noninvasive or nonpathogenic bacteria. Further, PCT International Publication Number WO 96/11277 describes the delivery of therapeutic compounds to an animal or human by administering a recombinant bacterium encoding a therapeutic protein. Steidler et al. (2000) describe the treatment of colitis by administration of a recombinant Lactococcus lactis secreting Interleukin-10. Such a delivery may indeed be extremely useful to treat a disease in an affected human or animal, but the recombinant bacterium may act as a harmful and pathogenic microorganism when it enters a nonaffected subject, and an efficient biological containment that avoids such unintentional spreading of the microorganism is needed.

Biological containment systems for host organisms may be passive and based on a strict requirement of the host for a specific growth factor or a nutrient that is not present or is present in low concentrations in the outside environment. Alternatively, it may be active and, based on so-called suicidal genetic elements in the host, wherein the host is killed in the outside environment by a cell-killing function, encoded by a gene that is under the control of a promoter only being expressed under specific environmental conditions.

Passive biological containment systems are well known in microorganisms such as Escherichia coli or Saccharomyces cerevisiae. Such E. coli strains are disclosed, for example, in U.S. Pat. No. 4,190,495. Also, PCT International Publication Number WO 95/10621 discloses lactic acid bacterial suppressor mutants and their use as means of containment in lactic acid bacteria, but in that case, the containment is on the plasmid level, rather than on the level of the host strain and it stabilizes the plasmid in the host strain, but does not provide containment for the genetically modified host strain itself.

Active suicidal systems have been described by several authors. Such systems consist of two elements: a lethal gene and a control sequence that switches on the expression of the lethal gene under nonpermissive conditions. For example, PCT International Publication Number WO 95/10614 discloses the use of a cytoplasmatically active truncated and/or mutated Staphylococcus aureus nuclease as a lethal gene. PCT International Publication Number WO 96/40947 discloses a recombinant bacterial system with environmentally limited viability, based on the expression of either an essential gene, expressed when the cell is in the permissive environment and not expressed or temporarily expressed when the cell is in the nonpermissive environment, and/or a lethal gene, wherein expression of the gene is lethal to the cell and the lethal gene is expressed when the cell is in the nonpermissive environment but not when the cell is in the permissive environment. PCT International Publication Number WO 99/58652 describes a biological containment system based on the relE cytotoxin. However, most systems have been elaborated for Escherichia coli (Tedkin et al., 1995; Knudsen et al., 1995; Schweder et al., 1995) or for Pseudomonas (Kaplan et al., 1999; Molino et al., 1998). Although several of the containment systems theoretically can by applied to lactic acid bacteria, no specific biological containment system for Lactococcus has been described that allows the usage of a self-containing and transformed Lactococcus to deliver prophylactic and/or therapeutic molecules in order to prevent and/or treat diseases.

DISCLOSURE OF THE INVENTION

The invention includes a suitable biological containment system for Lactococcus. A first aspect of the invention is an isolated strain of Lactococcus sp. comprising a defective thymidylate synthase gene.

Another aspect of the invention is the use of a strain according to the invention as a host strain for transformation, wherein the transforming plasmid does not comprise an intact thymidylate synthase gene.

Still another aspect of the invention is a transformed strain of Lactococcus sp. according to the invention, comprising a plasmid that does not comprise an intact thymidylate synthase gene. Another aspect of the invention relates to a transformed strain of Lactococcus sp. comprising a gene or expression unit encoding a prophylactic and/or therapeutic molecule such as Interleukin-10. Consequently, the present invention also relates to the usage of a transformed strain of Lactococcus sp. to deliver prophylactic and/or therapeutic molecules and, as such, to treat diseases. Methods to deliver the molecules and methods to treat diseases such as inflammatory bowel diseases are explained in detail in PCT International Publication Numbers WO 97/14806 and WO 00/23471 to Steidler et al. and in Steidler et al. (Science 2000, 289:1352), the contents of all of which are incorporated herein by this reference.

Another aspect of the invention is a medical preparation comprising a transformed strain of Lactococcus sp., according to the invention.

The invention further demonstrates that the transformed strains surprisingly pass the gut at the same speed as the control strains, showing that their loss of viability indeed is not different from that of the control strains. However, once the strain is secreted in the environment, for example, in the feces, it is not able to survive any longer.

The transforming plasmid can be any plasmid, as long as it does not complement the thyA mutation. It may be a self-replicating plasmid that preferably carries one or more genes of interest and one or more resistance markers, or it may be an integrative plasmid. In the latter case, the integrative plasmid itself may be used to create the mutation by causing integration at the thyA site, whereby the thyA gene is inactivated.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1: Map of the MG1363 thyA locus.

FIG. 2: Schematic representation of the different expression modules as present on pOThy plasmids ands genomic integrants of hIL-10. Black parts represent original L. lactis MG1363 genetic information; white parts represent recombinant genetic information.

FIGS. 3A and 3B: PCR identification of Thy11 (Thy11 1.1 and Thy11 7.1 represent individually obtained, identical clones). Standard PCR reactions were performed by using aliquots of saturated cultures of the indicated strains as a source of a DNA template. FIG. 3A shows an agarose gel of the products of the indicated PCR reactions. FIG. 3B shows the positions at which primers attach in the thyA (1), upstream (2) or downstream (3) PCR's. Oligonucleotide primers used:

  • (1): ATgACTTACgCAgATCAAgTTTTT (SEQ ID NO:8 of the accompanying SEQUENCE LISTING, which is incorporated herein by this reference and TTAAATTgCTAAATCAAATTTCAATTg. (SEQ ID NO:9)
  • (2): TCTgATTgAgTACCTTgACC (SEQ ID NO:10) and gCAATCATAATTggTTTTATTg (SEQ ID NO:11)
  • (3): CTTACATgACTATgAAAATCCg (SEQ ID NO:12) and cTTTTTTATTATTAgggAAAgCA (SEQ ID NO:13).

FIGS. 4A and 4B: PCR identification of Thy11, Thy12, Thy15 and Thy16. Standard PCR reactions were performed by using three-day old colonies of the indicated strains as a source of DNA template. FIG. 4A shows the positions at which primers attach in the upstream (1), downstream (2) or thyA (3), PCRs. Oligonucleotide primers used:

(1): ATgACTTACgCAgATCAAgTTTTT (SEQ ID NO: 8) and TTAAATTgCTAAATCAAATTTCAATTg (SEQ ID NO: 9) (2): TCTgATTgAgTACCTTgACC (SEQ ID NO: 10) and gCAATCATAATTggTTTTATTg (SEQ ID NO: 11) (3): CTTACATgACTATgAAAATCCg (SEQ ID NO: 12) and cTTTTTTATTATTAgggAAAgCA. (SEQ ID NO: 13)

FIG. 4B shows an agarose gel of the products of the indicated PCR reactions.

FIGS. 5A and 5B: Southern blot analysis of the indicated strains. Chromosomal DNA was extracted and digested with the indicated restriction enzymes. Following agarose gel electrophoresis, the DNA was transferred to a membrane and the chromosome structure around the thyA locus was revealed by use of DIG-labeled thyA or hIL-10 DNA fragments (FIG. 5A). FIG. 5B shows a schematic overview of the predicted structure of the thyA locus in both MG1363 and Thy11.

FIG. 6A shows a schematic overview of part of the predicted structure of the L. lactis chromosome at the thyA locus in MG1363, Thy11, Thy12, Thy15 and Thy16. Numbers indicate base pairs. FIG. 6B illustrates a Southern blot analysis of the indicated strains. Chromosomal DNA was extracted and digested with NdeI and SpeI restriction enzymes. Following agarose gel electrophoresis, the DNA was transferred to a membrane and the chromosome structure around the thyA locus was revealed by use of DIG-labeled thyA or hIL-10 DNA fragments.

FIGS. 7A and 7B: Production of hIL-10. FIG. 7A shows a western blot revealed with anti-hIL-10 antiserum of culture supernatant and cell-associated proteins of the indicated strains. FIG. 7B shows quantification (by ELISA) of hIL-10 present in the culture supernatant.

FIGS. 8A and 8B: Production of hIL-10. FIG. 8A shows quantification (by ELISA) of hIL-10 present in the culture supernatant of the indicated strains. FIG. 8B shows a western blot revealed with anti-hIL-10 antiserum of culture supernatant proteins of the indicated strains.

FIG. 9: Production of hIL-10 by the L. lactis strains LL108 carrying pOThy11, pOThy12, or pOThy16. Quantification (by ELISA) of hIL-10 present in the culture supernatant of the indicated strains is shown. The N-terminal protein sequence of the recombinant hIL-10 was determined by Edman degradation and was shown to be identical to the structure as predicted for the mature, recombinant hIL-10. The protein showed full biological activity.

FIGS. 10A and 10B: Growth rate of the indicated strains in GM17 containing 100 μg/ml (T100), 50 μg/ml (T50), 25 μg/ml (T25), or no (T0) extra thymidine and possibly supplemented with 5 μg/ml of erythromycin (E). Saturated overnight cultures (prepared in T50) were diluted 1:100 in the indicated culture media. FIG. 10A shows the kinetics of absorbance accumulation. FIG. 10B shows the kinetics of the number of colony-forming units (cfu) per ml of culture.

FIG. 11: Growth rate of MG1363 and Thy12 in thymidine-free medium (TFM). TFM was prepared by growing L. lactis Thy12 bacteria in GM17, removing the bacteria by subsequent centrifugation and filtration on a 0.22 μm pore size filter, adjusting the pH to 7.0 and autoclaving. MG1363 and Thy12 bacteria were collected from an overnight culture in GM17 or GM17+50 μg/ml of thymidine, respectively, and washed in M9 buffer (6 g/l Na2HPO4, 3 g/l KH2PO4, 1 g/l NH4Cl, 0.5 g/l NaCl in water). The suspensions of both were either diluted in TFM or TFM supplemented with 50 μg/ml of thymidine (T50). CFU counts were determined at different time points: t=0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 20 hours. This shows that Thy12 viability is severely impaired in the absence of thymidine.

FIG. 12: Intestinal passage and viability: L. lactis MG1363 was transformed with the plasmid pLET2N, which carries a chloramphenicol (Cm) resistance marker. L. lactis Thy12 was transformed with the plasmid pT1NX, which carries an erythromycin (Em) resistance marker. Of both strains, 109 bacteria were resuspended in BM9 (6 g/l Na2HPO4, 3 g/l KH2PO4, 1 g/l NH4Cl, 0.5 g/l NaCl in 25 mM NaHCO3+25 mM Na2CO3), mixed and inoculated in three mice at t=0 h. Feces were collected at the time intervals −1 to 0, 0 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8, 8 to 9, 9 to 10 and 10 to overnight. All samples were resuspended in isotonic buffer and appropriate dilutions were plated on GM 17 (M17 medium, Difco, St. Louis, Mo., supplemented with 0.5% glucose) plates containing either Cm, Em or Em+50 μg/ml thymidine. Colony-forming units for the different plates are represented in the graph.

 DETAILED DESCRIPTION OF THE INVENTION

As previously identified, the invention includes a suitable biological containment system for Lactococcus. In one aspect, the invention is an isolated strain of Lactococcus sp. comprising a defective thymidylate synthase gene. Preferably, the defective thymidylate synthase gene is inactivated by gene disruption. Even more preferably, the Lactococcus sp. is Lactococcus lactis. A special embodiment is a Lactococcus sp. strain, preferably Lactococcus lactis, more preferably a Lactococcus lactis MG1363 derivative, wherein the thymidylate synthase gene has been disrupted and replaced by an Interleukin-10 expression unit. The Interleukin-10 expression unit is preferably, but not limited to, a human Interleukin-10 expression unit or gene encoding for human Interleukin-10.

The Lactococcus lactis subsp. lactis thymidylate synthase gene (thyA) has been cloned by Ross et al. (1990a). Its sequence is comprised in SEQ ID NO:3 and SEQ ID NO:5. European Patent Application Publication Number 0406003 discloses a vector devoid of antibiotic resistance and bearing a thymidylate synthase gene as a selection marker; the same vector has been described by Ross et al. (1990b). However, this vector could not be used in a Lactococcus lactis strain due to the lack of a suitable thyA mutant that has never been described. The present invention discloses how to construct such a mutant by gene disruption using homologous recombination in Lactococcus. In a preferred embodiment, the thyA gene is disrupted by a functional human Interleukin-10 expression cassette. However, it is clear that any construct can be used for gene disruption, as long as it results in an inactivation of the thyA gene or in an inactive thymidylate synthase. As a nonlimiting example, the homologous recombination may result in a deletion of the gene, in one or more amino acid substitutions that lead to an inactive form of the thymidylate synthase, or in a frame shift mutation resulting in a truncated form of the protein.

Such a Lactococcus sp. thyA mutant is very useful as a host strain for transformation in situations where more severe containment than purely physical containment is needed. Indeed, thyA mutants cannot survive in an environment without or with only a limited concentration of thymidine and/or thymine. When such a strain is transformed with a plasmid that does not comprise an intact thyA gene and cannot complement the mutation, the transformed strain will become suicidal in a thymidine/thymine-poor environment. Such a strain can be used in a fermentor as an additional protection for the physical containment. Moreover, the present invention discloses that such a strain is especially useful in cases where the strain is used as a delivery vehicle in an animal body. Indeed, when such a transformed strain is given, for example, orally to an animal—including humans—it survives in the gut, provided that a sufficiently high concentration of thymidine/thymine is present, and produces homologous and/or heterologous proteins, such as human Interleukin-10, that may be beneficial for the animal.

The invention further demonstrates that the transformed strains surprisingly pass the gut at the same speed as the control strains, showing that their loss of viability indeed is not different from that of the control strains. However, once the strain is secreted in the environment, for example, in the feces, it is not able to survive any longer.

The transforming plasmid can be any plasmid, as long as it does not complement the thyA mutation. It may be a self-replicating plasmid that preferably carries one or more genes of interest and one or more resistance markers, or it may be an integrative plasmid. In the latter case, the integrative plasmid itself may be used to create the mutation by causing integration at the thyA site, whereby the thyA gene is inactivated. Preferably, the active thyA gene is replaced by double homologous recombination by a cassette comprising the gene or genes of interest, flanked by targeting sequences that target the insertion to the thyA target site. It is of extreme importance that these sequences are sufficiently long and sufficiently homologous to integrate the sequence into the target site. Preferably, the targeting sequences include at least 100 contiguous nucleotides of SEQ ID NO:1 at one side of the gene of interest and at least 100 contiguous nucleotides of SEQ ID NO:2 at the other side. More preferably, the targeting sequences consist of at least 500 contiguous nucleotides of SEQ ID NO:1 at one side of the gene of interest and at least 500 contiguous nucleotides of SEQ ID NO:2 at the other side. Most preferably, the targeting sequences consist of SEQ ID NO:1 at one side of the gene of interest and SEQ ID NO:2 at the other side, or the targeting sequences consist of at least 100 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID NO:1 at one side of the gene of interest and at least 100 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID NO:2 at the other side of the gene of interest. Preferably, the targeting sequences consist of at least 500 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID NO:1 at one side of the gene of interest and at least 500 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID NO:2 at the other side of the gene of interest. Most preferably, the targeting sequences consist of at least 1000 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID NO:1 at one side of the gene of interest and at least 1000 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID NO:2 at the other side of the gene of interest. The percentage identity is measured with BLAST, according to Altschul et al. (1997). A preferred example of a sequence homologous to SEQ ID NO:1 is given in SEQ ID NO:7. For the purpose of the invention, SEQ ID NO:1 and SEQ ID NO:7 are interchangeable.

Transformation methods of Lactococcus are known to the person skilled in the art and include, but are not limited to, protoplast transformation and electroporation.

A transformed Lactococcus sp. strain according to the invention is useful for the delivery of prophylactic and/or therapeutic molecules and can be used in a pharmaceutical composition. The delivery of such molecules has been disclosed, as a nonlimiting example, in PCT International Publication Numbers WO 97/14806 and WO 98/31786. Prophylactic and/or therapeutic molecules include, but are not limited to, polypeptides such as insulin, growth hormone, prolactin, calcitonin, group 1 cytokines, group 2 cytokines and group 3 cytokines and polysaccharides such as polysaccharide antigens from pathogenic bacteria. A preferred embodiment is the use of a Lactococcus sp. strain according to the invention to deliver human Interleukin-10. This strain can be used in the manufacture of a medicament to treat Crohn's disease as indicated herein.

The invention is further explained with the use of the following illustrative examples.

EXAMPLES

From L. lactis MG1363 (Gasson, 1983) regions flanking the sequence according to Ross et al. (1990a) have been cloned.

The knowledge of these sequences is of critical importance for the genetic engineering of any Lactococcus strain in a way as described below, as the strategy will employ double homologous recombination in the areas of 1000 bp at the 5′ end (SEQ ID NO:1) and 1000 bp at the 3′ end (SEQ ID NO:2) of thyA, the “thyA target.” These sequences are not available from any public source to date. These flanking DNA fragments have been cloned and their sequence has been identified. The sequence of the whole locus is shown in SEQ ID NO:3; a mutant version of this sequence is shown in SEQ ID NO:5. Both the 5′ and 3′ sequences are different from the sequence at GenBank AE006385 describing the L. lactis IL1403 sequence. (Bolotin, in press) or at AF336368 describing the L. lactis subsp. lactis CHCC373 sequence. From the literature, it is apparent that homologous recombination by use of the published sequences adjacent to thyA (Ross et al., 1990a) (86 bp at the 5′ end and 31 bp at the 3′ end) is virtually impossible due to the shortness of the sequences. Indeed, Biswas et al. (1993) describe a logarithmically decreasing correlation between the length of the homologous sequences and the frequency of integration. The sequences of L. lactis Thy 11, Thy 12, Thy 15 and Thy 16 at the thyA locus as determined in the present invention are given by SEQ ID NOS:19, 20, 21, 22 respectively.

The thyA replacement is performed by making suitable replacements in a plasmid-borne version of the thyA target, as described below. The carrier plasmid is a derivative of pORI19 (Law et al., 1995), a replication-defective plasmid, which only transfers the erythromycin resistance to a given strain when a first homologous recombination, at either the 5′ 1000 bp or at the 3′ 1000 bp of the thyA target. A second homologous recombination at the 3′ 1000 bp or at the 5′ 1000 bp of the thyA target yields the desired strain.

The thyA gene is replaced by a synthetic gene encoding a protein which has the L. lactis Usp45 secretion leader (van Asseldonk et al., 1990) fused to a protein of an identical amino-acid sequence when: (a) the mature part of human-Interleukin 10 (hIL-10) or (b) the mature part of hIL-10 in which proline at position 2 has been replaced with alanine or (c) the mature part of hIL-10 in which the first two amino acids have been deleted; (a), (b) and (c) are called hIL-10 analogs, the fusion products are called Usp45-hIL-10.

The thyA gene is replaced by an expression unit comprising the lactococcal P1 promoter (Waterfield et al., 1995), the E. coli bacteriophageT7 expression signals, putative RNA stabilizing sequence and modified gene10 ribosomal binding site (Wells and Schofield, 1996).

At the 5′ end, the insertion is performed in such way that the ATG of thyA is fused to the P1-T7Usp45-hIL-10 expression unit.

5′ agataggaaaatttcatgacttacgcagatcaagttttt...thyA wild-type (SEQ ID NO: 27)          gattaagtcatcttacctctt...P1-T7-usp45-hIL10 (SEQ ID NO: 14) 5′ agataggaaaatttcatggattaagtcatcttacctctt...thyA−, P1-T7-usp45-hIL10 (SEQ ID NO: 15)

Alternatively, at the 5′ end, the insertion is performed in such a way that the thyA ATG is not included:

5′ agataggaaaatttcacttacgcagatcaagttttt...thyA wild-type (SEQ ID NO: 28)          gattaagtcatcttacctctt...P1-T7-usp45-hIL10 (SEQ ID NO: 14) 5′ agataggaaaatttcgattaagtcatcttacctctt...thYA−,P1-T7-usp45-hIL10 (SEQ ID NO: 16)

Alternatively, at the 5′ end, the insertion is performed in such a way that the thyA promoter (Ross, 1990 a) is not included:

5′ tctgagaggttattttgggaaatactattgaaccatatcgaggtgtgtggtataatgaagggaattaaaaaa (SEQ ID NO: 29) gataggaaaatttcatg...thyA wild-type           gattaagtcatcttacctctt...P1-T7-usp45-hIL10 (SEQ ID NO: 29) 5′ tctgagaggttattttgggaaatactagattaagtcatcttacctctt...thyA−,P1-T7-usp45-hIL10 (SEQ ID NO: 14)

At the 3′ end, an ACTAGT SpeI restriction site was engineered immediately adjacent to the TAA stop codon of the usp45-hIL-10 sequence. This was ligated in a TCTAGA XbaI restriction site, which was engineered immediately following the thyA stop codon

aaaatccgtaactaactagt 3′...usp45-hIL10 (SEQ ID NO: 30) gatttagcaatttaaattaaattaatctataagtt 3′...thyA-wild-type (SEQ ID NO: 31)          tctagaattaatctataagttactga 3′...engineered thyA target (SEQ ID NO: 32) aaaatccgtaactaactaga attaatctataagttactga 3′...thyA−,usp45-hIL10 (SEQ ID NO: 18)

These constructs are depicted in FIG. 2. The sequences of pOThy11, pOThy12 pOThy15 and pOThy16 are given by SEQ ID NOs: 23, 24, 25, and 26 respectively. The resulting strains are thyA deficient, a mutant not yet described for L. lactis. It is strictly dependent upon the addition of thymine or thymidine for growth.

The map of the deletion, as well as the PCR analysis of all the isolates/mutants of the present invention, is shown in FIGS. 3A-4B. The presence of the thymidylate synthase and the Interleukin 10 (IL-10) gene in the wild-type strain and in the independent isolates/mutant was analyzed by Southern analysis as shown in FIGS. 5A-6B. The region around the inserted hIL-10 gene was isolated by PCR and the DNA sequence was verified. The structure is identical to the predicted sequence.

Human Interleukin-10 (hIL-10) production in the mutants was checked by western blot analysis and compared with the parental strain, transformed with pTREX1 as negative control, and the parental strain, transformed with the IL10-producing plasmid pT1HIL10apxa as a positive control (FIG. 7A). The concentration in the culture supernatant was quantified using ELISA. As shown in FIG. 7B, both isolates of the mutant produce a comparable, significant amount of hIL-10, be it far less than the strain, transformed with the nonintegrative plasmid pT1HIL10apxa. FIGS. 8A and 8B further demonstrate that all mutants produce a significant amount of hIL-10.

FIG. 9 shows the production of hIL-10 by the L. lactis strains LL108 carrying pOThy11, pOThy12, or pOThy16. Quantification (by ELISA) of hIL-10 present in the culture supernatant of the indicated strains is shown. The N-terminal protein sequence of the recombinant hIL-10 was determined by Edman degradation and was shown to be identical to the structure as predicted for the mature, recombinant hIL-10. The protein showed full biological activity. LL108 is an L. lactis strain carrying a genomic integration of the repA gene, required for replication of pORI19 derived plasmids such as pOThy11, pOThy12, pOThy15 or pOThy16. This strain was kindly donated by Dr. Jan Kok, University of Groningen, The Netherlands. The plasmids pOThy11, pOThy12, pOThy15 and pOThy16 carry the synthetic human IL-10 gene in different promoter configurations (see FIG. 2), flanked by approximately 1 kB of genomic DNA derived from the thyA locus, upstream and downstream from thyA. These plasmids were used for the construction of the genomic integration as described.

The effect of the thymidylate synthase deletion on the growth in thymidine less and thymidine-supplemented media was tested; the results are summarized in FIGS. 10 and 11. An absence of thymidine in the medium strongly limits the growth of the mutant and even results in a decrease of colony-forming units after four hours of cultivation. The addition of thymidine to the medium results in an identical growth curve and amount of colony-forming units, compared to the wild-type strain, indicating that the mutant does not affect the growth or viability in thymidine-supplemented medium. FIG. 11 clearly demonstrates that Thy12 viability is severely impaired in the absence of thymidine.

FIG. 12 finally shows that L. lactis Thy12 passes through the intestine of the mice at the same speed as MG1363. Loss of viability does not appear to differ between Thy12 and MG1363. Thy12 appears fully dependent on thymidine for growth, indicating that no Thy12 bacteria had taken up a foreign thyA gene.

REFERENCES

  • Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W. and Lipman D. J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402.
  • Biswas, I., Gruss, A., Ehrlich, S. D. et al. (1993) High-efficiency gene inactivation and replacement system for gram-positive bacteria. J. Bacteriol. 175, 3628-3635.
  • Gasson, M. J. (1983). Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol. 154, 1-9.
  • Kaplan, D. L., Mello, C., Sano, T., Cantor, C. and Smith, C. (1999). Streptavidin-based containment system for genetically engineered microorganisms. Biomol. Eng. 31, 135-140.
  • Knudsen, S., Saadbye, P., Hansen, L. H., Collier, A., Jacobsen, B. L., Schlundt, J. And Karlstrom, O. H. (1995). Development and testing of improved suicide functions for biological containment of bacteria. Appl. Environ. Microbiol. 61, 985-991.
  • Law, J., Buist, G., Haandrikman, A. et al. (1995). A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes. J Bacteriol. 177, 7011-7018.
  • Molina, L., Ramos, C., Ronchel, M. C., Molin, S. and Ramos, J. L. (1998). Construction of an efficient biologically contained Pseudomonas putida strain and its survival in outdoor assays. Appl. Environ. Microbiol. 64, 2072-2078.
  • Ross, P., O'Gara, F. and Condon, S. (1990a). Cloning and characterization of the thymidylate synthase gene from Lactococcus lactis subsp. Lactis. Appl. Environ. Microbiol. 56, 2156-2163.
  • Ross, P., O'Gara, F. and Condon, S. (1990b). Thymidylate synthase gene from Lactococcus lactis as a genetic marker: an alternative to antibiotic resistance. Appl. Environ. Microbiol 56, 2164-2169.
  • Schweder, T., Hofinann, K. And Hecker, M. (1995). Escherichia coli K12 relA strains as safe hosts for expression of recombinant DNA. Appl. Environ. Microbiol. 42, 718-723.
  • Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., Fiers, W. and Remaut, E. (2000). Treatment of murine colitis by Lactococcus lactis secreting Interleukin-10. Science 289, 1352-1355.
  • Steidler, L., Wells, J. M., Raeymaekers, A., Vandekerckhove, J., Fiers, W. And Remaut, E. (1995). Secretion of biologically active murine Interleukin-2 by Lactococcus lactis subsp. Lactis. Appl. Environ. Microbiol. 61, 1627-1629.
  • Tedin, K. Witte, A., Reisinger, G., Lubitz, W. and Basi, U. (1995). Evaluation of the E. coli ribosomal rrnB P1 promoter and phage derived lysis genes for the use in biological containment system: a concept study. J. Biotechnol. 39, 137-148.
  • van Asseldonk, M., Rutten, G., Oteman, M. et al. (1990). Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. Gene 95, 155-160.
  • Waterfield, N. R., Le Page, R. W., Wilson, P. W. et al. (1995) The isolation of lactococcal promoters and their use in investigating bacterial luciferase synthesis in Lactococcus lactis. Gene 165, 9-15.
  • Wells, J. M. and Schofield, K. M. (1996) Cloning and expression vectors for Lactococci. Nato ASI series H98, 37-62.

Claims

1. An isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species, said thyA mutant comprising:

an inactive Lactococcus thymidylate synthase gene; and
a gene encoding a heterologous therapeutic molecule;
wherein said parent strain comprises SEQ ID NO: 3 and or SEQ ID NO: 5,
wherein the thyA mutant expresses the heterologous therapeutic molecule.

2. The isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species of claim 1, wherein said (thyA) mutant is transformed with a transforming plasmid, wherein said transforming plasmid does not encode an active thymidylate synthase.

3. The isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species of claim 2, wherein the transforming plasmid comprises the gene encoding a heterologous therapeutic molecule.

4. The isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species of any one of claims 2, 3, or 1, wherein the Lactococcus species is Lactococcus lactis.

5. The isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species of any one of claim 2, 3, or 1, wherein the gene encoding a heterologous therapeutic molecule encodes Interleukin-10.

6. The isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species of any one of claims 2, 3, or 1, wherein the gene encoding a heterologous therapeutic molecule encodes Interleukin-10 and wherein the Lactococcus species is Lactococcus lactis.

7. An isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species, the thyA mutant comprising: wherein the parent strain of Lactococcus species comprises:

an inactive Lactococcus thymidylate synthase gene and a gene encoding a heterologous therapeutic molecule, wherein the inactive Lactococcus thymidylate synthase gene has been inactivated by gene disruption;
SEQ ID NO: 3 or SEQ ID NO: 5, and wherein the thyA mutant expresses the heterologous therapeutic molecule.

8. An isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species, wherein the thyA mutant lacks active Lactococcus thymidylate synthase gene and comprises a gene encoding a heterologous therapeutic molecule, wherein the thyA mutant expresses the heterologous therapeutic molecule, and wherein the thyA mutant is produced by a process comprising:

providing a parent strain of Lactococcus species comprising a thymidylate synthase gene comprising wherein said Lactococcus thymidylate synthase gene comprises SEQ ID NO: 3 or SEQ ID NO: 5; and
altering by gene disruption the Lactococcus thymidylate synthase gene of the parent strain so as to inactivate the thymidylate synthase encoded thereby.

9. The isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species according to claim 8, wherein the gene encoding the heterologous therapeutic molecule is integrated within, or replaces at least a part of the thymidylate synthase gene of said parent strain.

10. The isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species according to claim 8, wherein said (thyA) mutant is transformed with a transforming plasmid,

wherein said transforming plasmid does not encode an active thymidylate synthase.

11. The isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species according to claim 10, wherein the transforming plasmid comprises the gene encoding a heterologous therapeutic molecule.

12. The isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species according to any of claims 8, 9, 10 or 11, wherein the Lactococcus species is Lactococcus lactis.

13. The isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species according to any of claims 8, 9, 10, or 11, wherein the gene encoding a heterologous therapeutic molecule encodes Interleukin-10.

14. The isolated thymidylate synthase (thyA) mutant of a parent strain of Lactococcus species according to any of claims 8, 9, 10, or 11, wherein the gene encoding a heterologous therapeutic molecule encodes Interleukin-10 and wherein the Lactococcus species is Lactococcus lactis.

15. A composition comprising:

the isolated thymidylate synthase (thyA) mutant of claim 1.

16. The composition of claim 15, wherein said (thyA) mutant is transformed with a transforming plasmid, wherein said transforming plasmid does not encode an active thymidylate synthase.

17. The composition of claim 16, wherein the transforming plasmid comprises the gene encoding a heterologous therapeutic molecule.

18. The composition of any of claim 15, 17, or 16, wherein the gene encoding a heterologous therapeutic molecule encodes Interleukin-10.

19. The composition of any of claim 15, 17, or 16, wherein said Lactococcus species is Lactococcus lactis.

20. The composition of any of claim 15, 17, or 16, wherein the gene encoding a heterologous therapeutic molecule encodes Interleukin-10 and wherein said Lactococcus species is Lactococcus lactis.

21. A method for delivering a heterologous therapeutic molecule to a subject, said method comprising administering the transformed strain of Lactococcus species of any of claims 1, 7, and 8 to the subject.

22. A method for delivering a heterologous molecule to a human subject, the method comprising administering the Lactococcus species of any of claims 1, 7, and 8 to the human subject.

23. A method of treating inflammatory bowel disease in a subject, said method comprising:

administering to the subject a transformed strain of Lactococcus species of any of claims 1, 7, and 8.

24. The method of claim 23, wherein the gene encoding a heterologous therapeutic molecule encodes Interleukin-10.

Referenced Cited
U.S. Patent Documents
4100495 July 11, 1978 Luvison et al.
4190495 February 26, 1980 Curtiss, III
4888170 December 19, 1989 Curtiss, III
5032510 July 16, 1991 Kovacevic et al.
5149532 September 22, 1992 Brunell
5240705 August 31, 1993 Jacobs
5330753 July 19, 1994 Mekalanos et al.
5364774 November 15, 1994 Muir et al.
5401642 March 28, 1995 Fiers et al.
5401658 March 28, 1995 Fiers et al.
5417986 May 23, 1995 Reid et al.
5455034 October 3, 1995 Nagaraja et al.
5504005 April 2, 1996 Bloom et al.
5547664 August 20, 1996 Charles et al.
5559007 September 24, 1996 Suri et al.
5591632 January 7, 1997 O'Donnell et al.
5733540 March 31, 1998 Lee
5824538 October 20, 1998 Branstrom et al.
5837409 November 17, 1998 Bertrand et al.
6100388 August 8, 2000 Casas et al.
6130082 October 10, 2000 Majarian et al.
6190662 February 20, 2001 Steidler et al.
6190669 February 20, 2001 Noriega et al.
6221648 April 24, 2001 Le Page et al.
6261561 July 17, 2001 Stewart, Jr. et al.
6262119 July 17, 2001 Ferrante et al.
6605286 August 12, 2003 Steidler
6610300 August 26, 2003 Segers et al.
6685943 February 3, 2004 Hook et al.
6746671 June 8, 2004 Steidler et al.
7358067 April 15, 2008 Vrang et al.
20010006642 July 5, 2001 Steidler et al.
20020019043 February 14, 2002 Steidler et al.
20030202991 October 30, 2003 Steidler et al.
20030203472 October 30, 2003 Portnoy et al.
20040043003 March 4, 2004 Chen et al.
Foreign Patent Documents
42 31 764 March 1994 DE
0 176 320 April 1986 EP
0 406 003 January 1991 EP
0 449 770 October 1991 EP
0 450 176 October 1991 EP
WO 88/06626 September 1988 WO
WO 91/06654 May 1991 WO
WO 93/17117 September 1993 WO
WO 95/03418 February 1995 WO
WO 95/10614 April 1995 WO
WO 95/10621 April 1995 WO
WO 96/11277 April 1996 WO
WO 96/32487 October 1996 WO
WO 96/40947 December 1996 WO
WO 97/14806 April 1997 WO
WO 98/31786 July 1998 WO
WO 99/58652 November 1999 WO
WO 00/01799 January 2000 WO
WO 00/23471 April 2000 WO
WO 02/090551 November 2002 WO
WO 03/096979 November 2003 WO
WO 2004/045392 June 2004 WO
WO 2004/046346 June 2004 WO
WO 2007/063075 June 2007 WO
WO 2008/090223 July 2008 WO
Other references
  • Steidler et al (Jul. 2003) Nature Biotechnology, vol. 21, No. 7, pp. 785-789.
  • Ross et al. (1990) App. Environ. Microbiology, vol. 56, pp. 2156-2163.
  • ATCC Catalog Search performed online on Nov. 17, 2009 at www.atcc.org/ATCCAdvanceCatalogSearch/tabid/112/default.aspx.
  • Ross, et al., Thymidylate Synthase Gene from Lactococcus lactis as a Genetic Marker: an Alternative to Antibiotic Resistance Genes, Applied and Environmental Microbiology, Jul. 1990, pp. 2164-2169, vol. 56, No. 7.
  • Schotte et al., Secretion of biologically active murine interleukin-10 by Lactococcus lactis, Enzyme and Microbial Technology, 2000, pp. 761-765, vol. 27.
  • Steidler et al., Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10, Science, Aug. 25, 2000, pp. 135-155, vol. 289.
  • Taylor et al., Molecular Characterization of the Cell Cycle-regulated Thymidylate Synthase Gene of Saccharomyces cerevisiae, The Journal of Biological Chemistry, Apr. 15, 1987, pp. 5298-5307, vol. 262, No. 11.
  • PCT International Search Report, PCT/EP02/04942, dated Jan. 13, 2003, 2 pages.
  • PCT International Preliminary Examination Report, PCT/EP02/04942, dated Sep. 16, 2003, 5 pages.
  • Leong-Morgenthaler et al.. Lactose Metabolism in Lactobacillus bulgaricus: Analysis of the Primary Structure and Expression of the Genes Involved, Journal of Bacteriology. Mar. 1991, pp. 1951.57, vol. 173. No. 6.
  • Curtiss Tables III, IV and V, from U.S. Patent 4,888.170.
  • Cytokines Final Brochure for Cytokine Therapies, The Food and Drug Administration and the New York Academy of Sciences, held on Mar. 26-27, 2009.
  • Designing bacteria and white cells to deliver drugs to the gut, The Lancet, Sep. 20. 2003, www.thelancet.com, vol. 362, p. 964, J. Bradbury.
  • Eizaguirre et al., Abstract, Effect of Growth Hormone, Epidermal Growth Factor, and Insulin and Bacterial Translocation in Experimental Short Bowel Syndrome, Journal of Pediatric Surgery, 2000, pp. 692-695, vol. 35, No. 5.
  • Elliott et al., Bacterial colonization and healing of gastric ulcers: the effects of epidermal growth factor. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, pp. G105-G112, vol. 278.
  • Farrell et al.. FEMS Microbiology Letters, 1995, 130:81-85.
  • U.S. Appl. No. 60/353,923, filed Jan. 31, 2002, Chen.
  • U.S. Appl. No. 60/353,964, filed Jan. 31, 2002, Chen.
  • U.S. Appl. No. 60/353,885, filed Jan. 31, 2002, Chen.
  • U.S. Appl. No. 60/401,465, filed Aug. 5, 2002, Chen.
  • Anderson, Human gene therapy, 1998, Nature, vol. 392.
  • Arslanoglu et al., 1998. Biotechnology Letters. pp. 917-921, vol. 20.
  • Bamba et al., Gastroentorol J., 1993, pp. 511-517, vol. 28, No. 4.
  • Barbara et al., interleukin 10 gene transfer prevents experimental colitis in rats, 2000, Gut, pp. 344-349, vol. 46.
  • Bellini et al., Production processes of recombinant IL-1beta from Bacillus subtilis: comparison between intracellular and exocellular expression. 1991, Journal of Biotechnology, pp. 177-192, vol. 18.
  • Bermudez-Humaran et al., J. Medical Microbiology, 2004. 53:427-433.
  • Bijlsma et al., TRENDS in Microbiology, 2003. 11/8:359-366.
  • Billman-Jacobe, Current Opinion in Biotechnology, 1996, 7:500-504.
  • Blast, Basic Local Alignment Search Tool, visited Jul. 7, 2009, <http://blast.ncbi.nlm.nih.gov/Blast.cgi. Alignment of unknown sequence to NCBI chromosome sequences.
  • Bojovic et al., Applied & Environ. Microbiol., 57/2:385-388 (1991).
  • Brett et al., Eur. J. Immunol., 23:1608-1614 (1993).
  • Chen et al., FEMS Microbiology Letters, 2003. 229:111-117.
  • Claverys et al., Gene, 1995, 164:123-128.
  • Curtiss Tables III, IV and V, from U.S. Patent 4,888,170, issued Dec. 19, 1989.
  • Cytokines Final Brochure for Cytokine Therapies, The Food and Drug Administration and The New York Academy of Sciences, held on Mar. 26-27, 2009.
  • Darji et al., J. Biotechnology, 1995, 43:205-212.
  • Designing bacteria and white cells to deliver drugs to the gut, The Lancet, Sep. 20, 2003, www.thelancet.com, vol. 362, p. 964, J. Bradbury.
  • Edwards et al., Infection & Immunity, 60/6:2514-2521 (1992).
  • Eizaguirre et al., Abstract, Effect of Growth Hormone, Epidermal Growth Factor, and Insulin and Bacterial Translocation in Experimental Short Bowel Syndrome, Journal of Pediatric Surgery, 2000, pp. 692-695, vol. 35, No. 5.
  • Elliott et al.. Bacterial colonization and healing of gastric ulcers: the effects of epidermal growth factor. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, pp. G105-G112, vol. 278.
  • English translation of the Japanese Office Action dated Apr. 7, 2009.
  • Figler et al., Archives Biochemistry and Biophysics, 2000, 376/1:34-46.
  • Fischetti et al., Current Opinion in Biotechnology, Oct. 1993, 4/5:603-610.
  • Fu et al., “Development of a chromosome-plasmid balanced lethal system for Lactobacillus acidophilus with thyA gene as selective marker,” Microbiol. Immunol., 2000, pp. 551-556, vol. 44, No. 7, Abst. only.
  • Gasson, Abstract, “In vivo genetic systems in lactic acid bacteria,” FEMS Microbiol., 1990, Rev. 87:43-60.
  • Gotz, J. Applied Bacteriology Symposium Supplement, 1990, 49S-53S.
  • Gutierrez et al., Appl. Microbial. Biotechnol., 2006, 72/1:41-51.
  • Hansson et al., J. Bacteriology, Jul. 1992, 174/13:4239-4245.
  • Hardin et al., Gut, 1999, pp. 26-32, vol. 44.
  • Hazebrouck et al., Applied and Environmental Microbiology, Dec. 2006, 72/12:7460-7467.
  • Heath et al., Abstract, Cytokines as immunological adjuvants. Vaccine, 1992, pp. 427-434, vol. 10, No. 7.
  • Hegedus et al., Gene, 1998, 207:241-249.
  • Herfarth et al., Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers, 1996, GUT, pp. 836-845, vol. 39, Abstr. only.
  • Holmes et al., Infection & Immunity, 66/10:4633-4639 (1998).
  • Huibregtse et al., Abstract, Induction of Antigen-specific Oral Tolerance by Genetically Modified Lactococcus lactis Delivering DQ8-specific Immunodominant Gliadin Epitopes to Gluten-sensitized Class II Transgenic Mice, Clinical Immunology, Jan. 1, 2007, pp. S53-S54, vol. 123.
  • Iwaki et al., Infection Immunity, 58/9:2929-2934 (1990).
  • Janssen et al., Microbial Pathogenesis, 1995, 19:193-201.
  • Jeong et al., Food Microbiology, 2006, 23:82-89.
  • Kingman, Trial Tests If Modified Bacteria Can Deliver to Gut Mucosa, Jun. 15, 2003, online, BioWorld Online.
  • Kitchener, Prisons without bars, Nature Reviews, Genetics. Aug. 2003, p. 577, vol. 4.
  • Koivula et al., Isolation and Characterization of Lactococcus lactis subsp. lactis Promoters, Applied and Environmental Microbiology, Feb. 1991, pp. 333-340. vol. 57, No. 2.
  • Kong et al., Secretion of Human Interleukin 2 by Recombinant Mycobacterium bovis BCG, Infection and Immunity, Mar. 1995, pp. 799-803, vol. 63. No. 3.
  • Korelitz et al., Immunosuppressive therapy of inflammatory bowel disease: A historical perspective, The Gastroenterologist 5 (2) : 141-152. (1995).
  • Kruisselbrink et al., Recombinant Lactobacillus Plantarum Inhibits Ouse Dust Mite-Specific T-Cell Responses, Clinical and Experimental Immunology, Oct. 1, 2001, pp. 2-08, vol. 126, No. 1.
  • Kuby, Cytokine receptors, 1994, Immunology. pp. 304-306, W.H. Freeman & Comp. (eds).
  • Kurahayashi et al., Effects of EGF administration in the intestinal adaptation in the rat after massive intestinal resection, Diagnostics and New Medicaments, 1991, pp. 1691-1701, vol. 28, No. 9.
  • Leach et al., the role of IL-10 in inflammatory bowel disease: “Of mice and men,” 1999, Toxicologic Pathology, pp. 123-133.
  • Leenhouts et al., Applied and Environmental Microbiology, Dec. 1998, 64/12:4736-4742.
  • Leenhouts et al., Applied and Environmental Microbiology. Sep. 1991, 57/9:2568-2575.
  • Leenhouts et al., J. Bacteriology. Aug. 1991, 173-15:4794-4798.
  • Leong et al.. Selective Induction of Immune Responses by Cytokines Coexpressed in Recombinant Fowlpox Virus, Journal of Virology, Dec. 1994. pp. 8125-8130, vol. 68, No. 12.
  • Liu et al., J. Applied Microbiology, 2005, 98:127-135.
  • Maassen et al., Abstract, Reduced experimental autoimmune Encephalomyelitis after intranasal and oral administration of recombinant Lactobacilli expressing myelin antigens, Vaccine, Dec. 1, 2003, pp. 4685-4693, vol. 21, No. 32.
  • Mayer et al.. Abstract, Therapeutic potential of oral tolerance, Nature Reviews Immunology, Jun. 2004. pp. 407-419, vol. 4, No. 6.
  • McCluskie et al., Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates, 1999, Molecular Medicine, pp. 287-300, vol. 5.
  • Merriam-Webster's Collegiate Dictionary, Tenth Edition, Springfield, Massachusetts, USA, 2001, p. 922.
  • Motamedi et al., Gene, 1995, 160:25-31.
  • Norton et al., FEMS Immunology and Medical Microbiology, 1996, 14:167-177.
  • Norton et al., FEMS Microbiology Letters, 1994, 120/3:249-256.
  • Norton et al., Progress in the Development of Lactococcus lactis as a Recombinant Mucosal Vaccine Delivery System, Folia Microbiologica, Jan. 1, 1995, pp. 225-230, vol. 40, No. 3.
  • Norton et al., Vaccine, 1997, 15(6/7):616-619.
  • Nottebrock et al., Thymidine Concentrations in Serum and Urine of Different Animal Species and Man, Biochemical Pharmacology, 1977, pp. 2175-2179, vol. 26, Pergamon Press. Great Britain.
  • Oggioni et al., Gene, 1996, 169:85-90.
  • Oggioni et al., Vaccine, 1995, 13/8:775-779.
  • Paccez et al., Vaccine, 2007, 24:4671-4680.
  • Page et al., Innovations in oral gene delivery: challenges and potentials, 2001, DDT, pp. 92-101, vol. 6.
  • Papadakis et al., Role of cytokine in the pathogenesis of inflammatory bowel disease, 2000, Annu. Rev. Med., vol. 51, pp. 289-298.
  • Platteeuw et al., Applied and Environmental Microbiology, 1996, 62/3:1008-1013.
  • Pouwels et al., International J. Food Microbiology, 1998, 41:155-167.
  • Pouwels et al., J. Biotechnology, 1996, 44:183-192.
  • Pozzi et al., Abstract, Research in Microbiology, 1990, 141/6:659-670.
  • Pozzi et al., Abstract, Research in Microbiology, 1992, 143/5:449-457.
  • Pozzi et al., Infection and Immunity, May 1992, 60/5:1902-1907.
  • Ramasany et al., Vaccine, 2006, 24:3900-08.
  • Rao et al., Eur. J. Phannacol., 1996, pp. 209-212, vol. 303, No. 3.
  • Rapoport, Current Opinion in Biotechnology, 1:21-27 (1990).
  • Reviriego et al., International Dairy Journal, 2007, 17-574-577.
  • Robinson et al., Nature Biotechnology. 1997, 15:653-57.
  • Rodriguez et al., International J. Food Microbiology, 2003, 80:101-116.
  • Salzet, Michel, “Leech Thrombin Inhibitors,” Current Pharmaceutical Design, 2002, pp. 493-503, vol. 8.
  • Samuelson et al., J. Bacteriology, Mar. 1995, 177/6:1470-1476.
  • Sasaki et al., “thyA as a Selection Marker in Construction of Food-Grade Host-Vector and Integration Systems for Streptococcus Thermophilus,” Applied and Environmental Microbiology, Mar. 2004, pp. 1858-1864, vol. 70, No. 3..
  • Scott et al., Abstract, FEMS Microbiology Ecology, Aug. 1998, 26/3:219-230.
  • Sham et al., Abstract, Epidermal Growth Factor Improves Nutritional Outcome in a Rat Model of Short Bowel Syndrome, Journal of Pediatric Surgery, 2002, pp. 765-769, vol. 37, No. 5.
  • Sibakov et al., Applied & Environ. Microbiol., 57/2:341-348 (1991).
  • Slos et al., FEMS Microbiology Letters, 1998, 169:29-36.
  • Steidler et al., Secretion of Biologically Active Murine Interleukin-2by Lactococcus lactis subsp. lactis, Appl. Environ, Microbiol., 1995, 61:1627-1629.
  • Steidler et al., J. Bacteriol. 175/23:7639-7643 (1993).
  • Steidler et al., Mucosal Delivery of Murine Interleukin-2 (IL-2) and IL-6 by recombinant Strains of Lactococcus lactis Coexpressing Antigen and Cytokine, Infection and Immunity, 1998, pp. 3183-3189 vol. 66, No. 7:.
  • Steidler et al., NATO ASI Series vol. H98, pp. 63-79 (1996).
  • Steidler et al., Therapeutic drug delivery by genetically modified Lactococcus lactis, Annals of the New York Academy of Sciences, 2006, pp. 176-186, Abstr. only.
  • Stern, et al., Abstract, Microscopy Research and Technique, 2000, pp. 138-148, vol. 51.
  • Targan et al., Clarifying the causes of Croh's, 1995, Nature Medicine, pp. 1241-1243, vol. 1.
  • Thompson et al., Plasmid, 2001, 46:188-201.
  • Van De Guchte et al., Applied and Environmental Microbiology, Jan. 1989, 55/1:224-228.
  • Van De Guchte et al., Heterologous Gene Expression in Lactococcus lactis subsp. lactis: Synthesis, Secretion, and Processing of the Bacillus subtilis Neutral Protease, Applied and Environmental Microbiology, Sep. 1990, p. 2606-2611, vol. 56, No. 9.
  • Van Mallaert et al., Med. Fac. Landbouww, Rijksuniv. Gent., 1989, 54(4b):1477-1485.
  • Verma et al., Gene therapy—promises: problems and prospects, 1997, Nature, pp. 239-242, vol. 389.
  • Waterfield et al., Gene. 1995, 165:9-15.
  • Wells et al., Applied & Environ. Microbiol., 59/11:3954-3959 (1993).
  • Wells et al., International Dairy Journal, 1995, 5:1071-1079.
  • Wells et al., Lactic acid bacteria as vaccine delivery vehicles, Antonie van Leeuwenhoek 70:317-330 (1996).
  • Wells et al., Molecular Microbiol. 8/6:1155-1162 (1993).
  • Wiedermann, Abstract, Prophylaxis and therapy of allergy by mucosal tolerance induction with recombinant allergens or allergen constructs, Current Drug Targets, Inflammation and Allergy, Oct. 1, 2005, pp. 577-83, vol. 4. No. 5, Bentham Science Publishers.
  • Williams et al., Plasmid, 2002, 47:241-245.
  • Willis, Bacterial drug delivery, Newsinbrief, online (after Jun. 15, 2003).
  • Notice of Allowance for U.S. Appl. No. 11/018,188 dated Apr. 8, 2009.
  • Office Action for U.S. Appl. No. 11/127,921 dated Mar. 10, 2009.
Patent History
Patent number: 7780961
Type: Grant
Filed: Oct 17, 2003
Date of Patent: Aug 24, 2010
Patent Publication Number: 20050101005
Assignee: Actogenix N.V. (Zwijnaarde)
Inventor: Lothar Steidler (Bandon)
Primary Examiner: Rebecca E. Prouty
Attorney: TraskBritt
Application Number: 10/687,996